Pneumagen
Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.
Total raised
€9.0M
€9,017,597
Funding rounds
2
Investors
2
distinct backers
Active since
2020-05
latest 2022-01
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood12
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
Exit likelihood13
base rate 12% (2+ rounds)
- ▲ 10y since founding
Timing: dormant vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-01-19 | Other | €4.6M | Scottish Enterprise,Thairm Bio | View deal → |
| 2020-05-27 | Early VC | €4.5M | Thairm Bio | View deal → |
Investors
2Related news
- Pneumagen Raises £3.8M in Fundingfinsmes.com · 2022-01
- finsmes.com